Brooklyn ImmunoTherapeutics Inc

ASE:BTX   3:59:50 PM EDT
10.61
+0.35 (+3.41%)
Mergers / Acquisitions

Brooklyn Immunotherapeutics Executes Letter Of Intent To Acquire Novellus Therapeutics

Published: 06/14/2021 11:50 GMT
Brooklyn ImmunoTherapeutics Inc (BTX) - Brooklyn Immunotherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics.
Brooklyn Immunotherapeutics Inc - Expected That Transaction Will Involve an Acquisition by Brooklyn of All of Outstanding Equity of Novellus.
Brooklyn Immunotherapeutics - Terms of Loi Value Novellus at $125.0 Million.
Brooklyn Immunotherapeutics - $125.0 Million is Proposed to Be Paid by Co by Combination of $17.4 Million in Cash and $107.6 Million in Btx Common Stock.